European Psychiatry - Volume 41 - April 2017

774 / 916

S770 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S710–S771
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1123
Depression and Parkinson’s disease:
Biological therapies
B. Mures ∗ . Lluis , A.P. I˜nigo , M.H. German , T.G. Miriam ,
R.Q. José , L.P. Yolanda
Hospital Clinico San Carlos, Psychyatry, Madrid, Spain
∗ Corresponding author.
Introduction Depression occurs in approximately 40% of patients
with Parkinson’s disease. Parkinson’s disease is commonly asso-
ciated with psychiatric morbidity, which includes depression,
anxiety, and dopaminergic psychosis. These compound the
patient’s predicament. Fortunately, a variety of effective treatments
are available.
Objective The purpose of this e-poster is to provide an update of
the research regarding depression in Parkinson’s disease.
Methods Describe a case report. A 56-year-old man, with previ-
ous diagnosis of Parkinson’s disease. We used SSRIs, but they was
not enough to successful treatment so we decided to use ECT.
Results Our patient failed to respond to medication or develop
intolerablemedication side effects. Electroconvulsive therapy (ECT)
should be considered for this group of patients. Contrary to popular
belief, ECT is a widely used and safe treatment for depression when
medication fails. ECT has been shown to be effective and safe in PD
for treating both depression and dopaminergic psychosis. Several
studies also report varying periods of motor improvement follow-
ing ECT in PD. A study is currently underway at UBC to examine this
phenomenon in a controlled setting. ECT improves depression, may
permit a reduction in antidepressant medications, and has intrinsic
antiparkinsonian properties.
Conclusions ECT, has repeatedly been shown to have beneficial
effects inPD, but has never gained acceptance as a clinical treatment
option. We review the literature on the use of ECT in PD, pointing
out that ECT has beneficial effects on both the coremotor symptoms
of PDaswell as the commonly occurring psychiatric co-morbidities.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1124
The role of neuroplasticity in the
treatment of cognitive impairments
by means multifactor
neuro-electrostimulation of the
segmental level of the autonomic
nervous system
T. Petrenko ∗, V. Kublanov , K. Retyunskiy
1 Ural Federal University, Research Medical and Biological
Engineering Center of the High Technologies, Ekaterinburg, Russia
2 Ural State Medical University, Department of Psychiatry,
Ekaterinburg, Russia
∗ Corresponding author.
Introduction Cognitive deficit is a consequence of organic lesions
of the central nervous system. Activation of neuroplasticity is a
way of effective treatment. There is a suppose that the autonomic
nervous system (ANS) involves in the regulation of neuroplasticity.
Objectives We developed a technology for non-invasive electrical
stimulate segmental and suprasegmental parts of ANS
Methods Developed technology is implemented in the
“SYMPATHOCOR–01” device. The device produces spatially dis-
tributed field of current pulses between two multiple electrodes
located on the neck. The targets of impact are cervical ganglia of
the sympathetic trunk and vagus nerve.
Results The restoration of blood supply in artificial ischemia
calf muscles and recovery of behavior patterns during acute
phase of the adjustment disorder were received as a result of
application technology in experiments on rats An increase
global neurometabolic activity on SPECT was shown in clini-
cal studies Application device for two weeks in children
with ADHD led to reduction of inattention and hyperactivity
symptoms
Conclusion We suggest that the demonstrated clinical effects are
the results of activate of neuroplasticity by impact on ANS struc-
tures. It is necessary to conduct fundamental studies by means of
neurovisualizationmethods (fMRI, PET) for the confirmation action
of these mechanisms.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
References
[1] Kublanov VS. A hardware-software system for diagnosis
and correction of autonomic dysfunctions. Biomed Eng
2008;42(4:):206–12.
[2] Kublanov VS, et al. Multi-electrode neurostimulation system
for treatment of cognitive impairments. In: Engineering in
Medicine and Biology Society, 37th Annual International Con-
ference of the IEEE. 2015. p. 2091–4.
EV1125
Modified electroconvulsive therapy in
pseudocholinesterase deficiency:
A case report
E. Yildizhan ∗, N.B. Tomruk , M. Dereli , A. Özdemir ,
H. Yıldırım , Ö. Canbek
1 Bakirkoy Research and Training Hospital for Psychiatry, Neurology
and Neurosurgery, Department of Psychiatry, Istanbul, Turkey
2 Bakirkoy Research and Training Hospital for Psychiatry, Neurology
and Neurosurgery, Department of Anesthesia and Reanimation,
Istanbul, Turkey
∗ Corresponding author.
Introduction Pseudocholinesterase (PCHE) deficiency is an inher-
ited condition, in which recovery from anesthetic agents like
succinylcholine andmivacurium is slow and complicated with pro-
longed paralysis of respiratory muscles in susceptible patients.
Succinylcholine is used very frequently as a muscle relaxant during
the procedure.
Objectives In Bakirkoy research and training hospital for psychi-
atric and neurological diseases, 24.310 patients were hospitalized
for acute conditions and 3490 of these patients were treated with
electroconvulsive therapy (ECT) in 3 years. We present a very rare
case that we encountered in our practice; a severe PCHE deficiency
case that could have complicated the modified ECT procedure
unless necessary precautions were taken.
Aims Detection of PCHE levels of all patients eligible for ECT is
part of our pre-ECT assessments procedure, and the case presented
here shows the benefits of this method.
Methods The patient is a 29-year-old woman, with a 15 year
history of schizophrenia. She was hospitalized for homicidal risk
and refusal of treatment. Inadequate clinical response with phar-
macological interventions and continuous aggressive excitations
directed us to consider ECT.
Results After the detection of PCHE deficiency (PCHE level: 126
U/L), we performed the modified ECT with propophol and rocuro-
nium instead of succinylcholine as usual. Sugammadex 100mg was
used for fastening the recovery. Response to treatment, which is
recorded with positive and negative syndrome scale, was good and
we completed 9 ECT sessions without complication.